Charles River's 33.3% monthly surge faces a higher bar as stronger bookings and guidance meet margin pressure and a premium valuation.

Stock Market Today: The Dow Jones index drops Thursday on Trump's "Economic D-Day" threat on Iran. Walmart dives on earnings.

Well-known pharmaceutical companies such as Merck and Pfizer typically manage this complex process in house. Medpace Holdings which targets oncology, metabolic, cardiology, central nervous system, and anti-infective therapies, raised its 2026 revenue guidance on July’s second-quarter conference call to a midpoint of $2.85 billion, corresponding to a year-over-year increase of 13%. Three months later, Medpace is in the pink: On the heels of second-quarter earnings, the stock is up 14%.

Management raised its full-year forecast, but the market seems to be asking for more than a higher target.

IQVIA shares jump 41.5% in three months as record R&DS bookings, a solid backlog, raised 2026 guidance and share buybacks support sentiment.

In late July and early August 2026, IQVIA Holdings and Medera announced a collaboration pairing IQVIA’s global clinical and commercialization infrastructure with Medera’s Sardocor and Novoheart cardiac gene therapy and human-based drug discovery platforms, alongside IQVIA’s second-quarter results, raised full-year 2026 revenue guidance to between US$17.28 billion and US$17.48 billion, and continued share repurchases. The partnership’s focus on AAV-based cardiac gene therapies and Novoheart’s...

By Exec Edge Editorial Staff IQVIA (NYSE: IQV) and clinical-stage biopharmaceutical company Medera Inc. announced a strategic collaboration aimed at accelerating the development of cardiac gene therapies and human-based drug discovery platforms. Under the partnership, Medera’s Sardocor unit will use IQVIA’s clinical trial, regulatory and commercialization capabilities to advance FDA-cleared, first-in-human gene therapy programs targeting […] The post IQVIA, Medera Partner to Accelerate Developme

ICLR's discounted valuation and $23.4B backlog support upside potential, but falling estimates, weaker margins and execution risks argue for patience.

Fiserv's Q2 revenues miss estimates and margin pressure leads to an earnings miss and cuts in its 2026 growth and profit outlook.

Medpace pairs double-digit growth, record awards and a strong balance sheet with a rich valuation, raising the question of whether the premium already prices in its outlook.

ICON's 33.2% rally is backed by stronger proposal flow, bookings and backlog, but weaker earnings and margins cloud the recovery.

Medpace posted record Q2 awards and a stronger book-to-bill ratio, but can backlog conversion and study timing turn renewed demand into stronger 2027 growth?

IQV's proprietary data platform and expanding clinical research business support growth, but high debt and liquidity risks keep the investment outlook balanced.

IQV shares jump after Q2 earnings beat, record bookings and higher 2026 guidance, but future gains hinge on execution and backlog conversion.

The global healthcare ecosystem in 2026 is leading to a strong recovery in clinical research, with global pharma R&D investment topping $250 billion and the clinical research organization (CRO) market rising to $72 billion at roughly a 9% annual pace. As biopharma companies move capital into complex biologic pipelines, AI-powered trial improvement, and practical data […]

The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.

This insider disposed of 16% of direct holdings at $245.21 per share, while maintaining nearly 3,000 shares valued at $740,000.

Sherbet's disposition leaves him with 20,999 directly held shares valued at $5.2 million as IQVIA trades near $238.

Bousbib exercised expiring stock appreciation rights while maintaining about 1.4 million shares in total beneficial ownership.

IQVIA Holdings just saw its internal fair value price target move from US$226.95 to US$232.00, a small reset in the reference point analysts are using. That shift sits against a mixed backdrop, with several firms lifting targets into the low to mid US$200s while at least one prominent analyst has moved to a more cautious US$200 view. As you read on, you will see how these changing targets fit into the evolving IQVIA story and what to watch as new research hits the tape. Analyst Price Targets...

WM beats Q2 earnings estimates as pricing and efficiency lift margins, but softer volumes lead revenues to miss expectations.

VRSK beats Q2 earnings and revenue estimates as subscription growth, Underwriting and Claims gains, and cost discipline supported the results.

IQVIA Holdings (IQV) stock moved after the company reported second quarter results that exceeded analyst estimates, raised full year 2026 revenue and earnings guidance, and expanded its share repurchase program, which highlighted management’s confidence in the business. See our latest analysis for IQVIA Holdings. The earnings beat and guidance raise have come on top of strong recent momentum, with a 90 day share price return of 55.07% and a 1 year total shareholder return of 24.87% suggesting...

The Morning Bull - US Market Morning Update Wednesday, Jul, 29 2026 US stock futures are mixed in early Tuesday trade, with broad S&P 500 contracts slightly in the red while Dow futures edge up. The key driver is the US 10 year Treasury yield hovering around 4.64% as investors brace for this week’s Federal Reserve decision. Markets see roughly a one in three chance of a rate hike now and about a 56% chance by September. At the same time, US durable goods orders for June rose 0.3% and a core...

Shares of clinical research company IQVIA (NYSE: IQV) jumped 12.9% in the morning session after the company reported second-quarter results that surpassed Wall Street's expectations and raised its full-year guidance. The company posted revenue of $4.37 billion, an 8.7% increase year-over-year, which beat estimates of $4.30 billion. Its adjusted earnings per share came in at $3.15, up 12.1% from the previous year and topping the consensus estimate of $3.03.

IQVIA Holdings Inc. (NYSE:IQV) extended its winning streak to a 4th straight session on Tuesday, jumping 13.94 percent to finish at $242.94 apiece after its higher revenue growth outlook and strong second-quarter performance reinforced investor confidence in its growth trajectory. In an updated report, the healthcare technology company said that it was able to grow […]

The headline numbers for IQVIA (IQV) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

IQVIA Holdings Inc (IQV) reports robust financial performance with significant gains in R&D Solutions and AI advancements driving future growth.

US equity indexes were mixed Tuesday as crude oil prices fell and semiconductor stocks led a pullbac

Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index rising 2.3% and

IQVIA (NYSE:IQV) reported second-quarter results that exceeded the high end of its guidance, supported by accelerating organic revenue growth, higher R&D Solutions bookings and operational productivity gains. The company also raised its full-year outlook for revenue, adjusted EBITDA and adjusted dil

IQVIA Holdings leads the index after the company boosted its full-year outlook on the back of a strong second quarter.

Moby summary of IQVIA Holdings Inc.'s Q2 2026 earnings call

(Updates with index/price moves, macroeconomic data, and company/geopolitical news from the first pa

Shares of Iqvia surged past a buy point Tuesday after the provider of clinical research services beat second-quarter estimates and raised guidance. The consensus earnings estimate was $3.03 per share, with the highest estimate at $3.08, according to FactSet. The backlog for its Research & Development Solutions business (which handles clinical trials) was $34.2 billion.

IQVIA's Q2 earnings beat estimates as record R&D bookings, broad-based growth and stronger demand support a raised 2026 outlook.

IQVIA (IQV) delivered earnings and revenue surprises of +4.31% and +1.63%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Clinical research company IQVIA (NYSE: IQV) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 8.7% year on year to $4.37 billion. The company’s full-year revenue guidance of $17.38 billion at the midpoint came in 0.5% above analysts’ estimates. Its non-GAAP profit of $3.15 per share was 3.9% above analysts’ consensus estimates.

Clinical research company IQVIA (NYSE: IQV) will be reporting earnings this Tuesday before market hours. Here’s what you need to know.

IQV heads into its Q2'26 earnings release with y/y revenue and EPS growth expected, supported by AI adoption, drug launches and high-margin segment gains.

Veracyte (VCYT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IQVIA (IQV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IQV vs. PEN: Which Stock Is the Better Value Option?